Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Mise à jour : Il y a 4 ans
Référence : NCT01210001

Femme et Homme

Extrait

This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.


Critère d'inclusion

  • Diabetes Mellitus, Type 2


Liens